- Affiliate Assistant Professor, Global Health
- Director, HPV Vaccine Programs, Center for Vaccine Innovation and Access, PATH
Center for Vaccine Innovation and Access: Policy, Access and Introduction functional area
2201 Westlake Avenue, Suite 200
Seattle, WA 98121
Select from the following:
D. Scott LaMontagne, PhD, MPH, FRSPH, CS, is an epidemiologist and director of HPV vaccine programs at PATH. He manages PATH's technical assistance team for national introductions of HPV vaccine in more than two dozen low- and middle-income countries. He is co-investigator for an HPV cost of delivery study in six countries, as well as technical officer for an alternative dosing schedule randomized controlled trial of a new bivalent HPV vaccine in Bangladesh and Ghana. He has authored and co-authored numerous papers on the clinical and operational aspects of HPV vaccine delivery in developing countries and is a recognized international expert in HPV vaccine delivery and evaluation in low-resource settings. Dr. LaMontagne has over 25 years of experience in infectious disease surveillance, operations and implementation research, public health program implementation, monitoring and evaluation, and project management for government and nongovernmental agencies at local, state, and national levels in developed and developing countries. He is a specialist in surveillance and epidemiology of human papillomavirus, Chlamydia trachomatis, tuberculosis, and sexually transmitted infections.
- PhD (Middlesex University)
- MPH (Yale University)
- BA (University of Washington)
- Adult Mortality
- Cervical Cancer
- Child and Adolescent Health (incl. Pediatrics)
- Delivery Logistics
- Health Policy
- Implementation Science
- Operations Research
- STDs (other than HIV)
Surveillance and epidemiology of TB and STI's
- A Phase 4 3 Randomized, Active-Comparator Controlled, Open-Label Trial to Evaluate the Immunogenicity and Safety of Alternate Two-Dose Regimens of a Bivalent Human Papillomavirus (HPV) Vaccine (Cecolin®) Compared to a Licensed Quadrivalent HPV Vaccine
- Continuing Technical Assistance to Gavi-eligible Countries for HPV Vaccine Introduction
- Evaluating the ongoing costs and operational context of national HPV vaccine delivery in six low- and middle-income countries.\
- The Single-Dose HPV Vaccine Evaluation Consortium
Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018 Mar 23. doi: 10.1016/j.vaccine.2018.02.003.
LaMontagne DS, Gallagher KE, Watson-Jones D. Why has HPV vaccine uptake lagged: a contextual reframing of vaccine introduction. HPV World 2017 Sep; 1(19):10-12.
LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C. Progress in HPV vaccination in low and lower-middle income countries. International Journal of Obstetrics & Gynecology 2017; 138(S1): 7-14.
Gallagher KE, Howard N, Kabakama S, Griffiths UK, Mounier-Jack S, Feletto M, LaMontagne DS, Burchett HED, Watson-Jones D. Lessons learnt from human papillomavirus vaccination in low- and middle-income countries. Public Library of Science (PLoS) One 2017; online 2 June 2017. https://doi.org/10.1371/journal.pone.0177773
LaMontagne DS, Cernushi T, Yabuku A, Bloem P, Watson-Jones D, Kim J. Chapter 15. In: Bundy DAP, de Silva N, Horton SE, Jamison DT, and Patton GC, eds. Disease Control Priorities. 3rd edn. Volume 8: child and adolescent health and development. Washington, D.C.: World Bank; 2018.